Endoglin has been reported to be highly expressed in the vasculature of various tumour types, including invasive breast carcinomas (Wang et al, 1994; Beresford et al, 2006), and predicts poor survival and poor clinical response to chemotherapy (Charpin-Taranger et al, 2003; Dales et al, 2004; Beresford et al, 2006). This evidence concerns the gene ENG and invasive breast carcinoma.